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Experimental models for IgA-associated nephritis
IgA-associated nephritis is characterized by the presence of
exclusively or predominantly glomerular IgA deposits, and
includes: primary IgA nephropathy [1—4], Schöhlein—Henoch
purpura [5, 6], and hepatic glomerulonephritis [7]. It is not clear
how the IgA mesangial deposits evolve and initiate immuno-
pathogenetic events that lead to morphological and functional
renal injury. Animal models provide investigative analogues to
these disorders. The following report summarizes studies on the
evolution and effect of IgA mesangial deposits in different
experimental models. The experimental pathophysiology of IgA
immune reactants are correlated to clinical findings of IgA-
associated nephritis in humans.
Animal Models
Immune complexes
The first experimental model for the study of IgA-associated
nephritis examined the nephritogenic potential of IgA immune
complexes in BALB/c mice [8]. In this model IgA immune
complexes (IgA-IC) were formed by using IgA from murine
myeloma (MOPC-315), which possess specific antigenic reac-
tivity for the dinitrophenyl (DNP) hapten, and bovine serum
albumin conjugated with DNP (DNP-BSA) as the antigen.
Immunoflouorescent staining of renal tissues revealed a diffuse—
global granular deposits of IgA and C3 in the glomeruli of all the
experimental animals, following passive administration of these
IgA-IC, although only 40% of the treated mice had hematuria.
The capacity of in vivo formed IgA-IC to induce renal
changes was also examined in mice bearing MPOC-315
myeloma. Animals with predetermined levels of circulating IgA
anti-DNP were repeatedly injected with DNP-BSA over a
six-day period. In these experiments, the degree of renal
histopathological changes was directly related to the level of
circulating IgA and the amount of antigen administered. Mice
with high levels of serum IgA anti-DNP exhibited most conspic-
uous morphologic changes. Thus, the ratio of antigen to anti-
body was not as critical as the concentration of the immune
reactants.
These experimental observations are of particular relevance
to IgA nephropathy and Schönlein—Henoch purpura. In these
diseases the granular immunofluorescent pattern and the
mesangial localization of the IgA and electron dense deposits
suggest a large—size aggregate. Such complexes are usually
formed in an environment of antibody excess [1]. The short
latent period between a respiratory or gastrointestinal infection
and the occurrence of hematuria would suggest that in these
disorders circulating IgA might be available to combine with
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small amounts of antigen released during infection, resulting in
formation of large—size immune complexes that deposit in the
kidneys [9].
The kinetics of glomerular IgA-IC deposition and disappear-
ance was determined in mice that received DNP-BSA followed
by the injection of IgA anti-DNP. Morphologic renal changes
were most prominent at 36 hours and disappeared 72 hours after
injection. In contrast, immunofluorescent staining revealed
persistence of IgA and DNP-BSA all through the 96 hour
observation period. Glomerular persistence of these complexes
contrasted sharply with their rapid elimination within few
minutes from the circulation [10]. Thus, absence of IgA-IC from
the circulation does not reflect a similar status in the glomeru-
lus.
Passive induction of glomerular IgA-IC was also achieved
utilizing a polysaccharide antigen [11]. In these studies, IgA-IC
were prepared in 40-fold antigen excess by mixing purified IgA
anti-dextran, obtained from murine myeloma, and dextrans
with restricted size and defined charge. These IgA-IC were
administered to normal mice that were sacrificed 34 hours later.
Despite extreme difference in antigenic charge (p1 <3 to >10)
and size (1 x l0 to 5 x l0 daltons), all the different IgA-IC
resulted in glomerular localization. By comparison, IgG-IC
formed in extreme antigen excess failed to deposit in renal
tissues [12]. These findings confirm the great propensity of
IgA-IC for glomerular deposition, even when formed in extreme
antigen excess.
The importance of IgA-IC in mediating renal injury, initially
established in the experimental model, has been confirmed by a
large number of clinical studies that demonstrated the presence
of IgA-IC in the circulation and renal tissues of patients with
primary IgA nephropathy [13—18], Schönlein—Henoch purpura
[19, 20], and liver cirrhosis—associated nephropathy [21, 22].
Systemic immunization
In the course of their studies on the role of antigenic charge
and size in chronic immune complex glomerulonephritis, Isaacs
and Miller [23] observed that mice developed IgA and 1gM
glomerular deposits in response to repeated injection of a
polysaccharide antigen. This model involved intraperitoneal
administration of beaded dextran followed by repeated intrave-
nous injection of soluble dextran, selected according to size (1
x i04 to 5 x i05 dalton) and charge (cationic, anionic, and
neutral). Morphologic changes induced by the immune depos-
its, over a 61 day period, were related mainly to the antigenic
charge. The neutral dextran led to mild focal, segmental,
proliferative response. The anionic dextran—sulfate elicited
diffuse mesangial proliferative response. Cationic diethylami-
noethyl—dextran—treated mice showed an increase in mesangial
matrix. Immunofluorescent staining showed a generalized gran-
ular pattern of IgA and to a lesser extent 1gM deposits in the
glomeruli of all the experimental animals. Approximately 80%
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of the experimental animals, noticeably the groups treated with
dextran—sulfate, showed C3 deposits. Although the temporal
relationship between IgA and 1gM deposition and the develop-
ment of histopathologic changes is unknown, these findings
emphasize the importance of antigenic size and charge in
governing renal immune complex deposition.
Generalization of these findings, however, cannot be made at
this time due to difficulties in reproducing the systemic immu-
nization model. Endoh et al (personal communication) con-
ducted similar studies; using the same antigen and immuniza-
tion protocol, they failed to induce an IgA or 1gM specific
anti-dextran response in Swiss—Webster mice. Furthermore,
they noted that experimental and control mice developed
spontaneous IgA renal deposits. Thus, the suggestion that this
model parallels the indolent nature of human IgA-associated
nephritis awaits further confirmation.
Oral immunization
To test the hypothesis that IgA nephropathy could result
from IgA that originated from stimulated mucosal immune
system, Emancipator, Gallo and Lamm [24] described a novel
approach for the induction of experimental IgA-associated
nephritis. In this model, three different protein antigens (bovine
gamma globulin, ovalbumin, or ferritin) were used, as 0.1%
drinking solution, for oral immunization of mice over a 14-week
period. Mesangial deposits of IgA, the specific antigen, and
electron dense material developed in 57% of the treated ani-
mals. In contrast, there was no difference in the background
mesangial level of IgG or 1gM in the control and treated groups.
The immune response was predominantly polymeric IgA (pIgA)
as determined by the detection of J-chain in the mesangial
deposits. An interesting aspect of this model is the absence of
C3 deposits and the mild histopathological changes.
This model, while delineating the importance of mucosal IgA
immune response, points to the importance of other unknown
factors or conditions that affect how the IgA-IC mediate renal
injury. Such factors may include: the nature of the antigen, the
size of the immune complex, and ability to activate comple-
ment.
Viral infection
The response of the mucosal immune system to viral infec-
tion and the resultant deposition of immune complexes in the
kidneys has been observed in lymphocytic choriomeningitis
(LCM) viral infection of mice [25]. In this model newborn mice
develop an IgG-IgA nephritis after experimental in utero infec-
tion with LCM virus. The immune complexes along with C3
were deposited in a granular distribution along the basement
membranes of the capillaries and in the mesangia. Nursing such
mice with virus—infected, immune, or noninfected mothers
indicated that the maternal antiviral IgG and IgA, of the
virus—infected or immune foster mothers, were responsible for
the early occurrence of glomerulonephritis.
Aleutian mink disease is another viral infection model in
which IgA renal deposits have been detected [26]. In this model
the immune reponse to a persistent parvovirus infection results
in an immune complex disease characterized by widespread
arteritis, chronic active hepatitis, and glomerular injury along
with interstitial nephritis [27]. The nature of the immune com-
plexes responsible for renal injury remains controversial. Pre-
dominantly IgG-viral complexes are detectable in the circula-
tion of infected animals [28]. Intense 1gM and to a lesser extent
IgG and IgA glomerular deposits are detectable in affected renal
tissues (D. Porter, personal communication). In contrast, Portis
and Coe [26] detected IgA and Bi C deposits in the kidneys of 28
minks afflicted with terminal Aleutian mink disease. These
deposits showed predominantly capillary and mesangial distri-
bution. Only seven of the 28 minks had demonstrable IgG
and/or 1gM renal deposits. Several aspects of this model,
however, are at variance with the clinico-pathologic features of
human IgA-associated nephritis. These include: marked IgG
hypergammaglobulinemia, generalized tissue plasmacytosis,
and invariably sub-epithelial glomerular deposits in infected
minks. The role of IgA in mediating renal injury in this disease
awaits further clarification.
Hepatobiliary dysfunction
The discovery of pIgA transport from plasma to bile by
secretory component (SC) in rat liver has stimulated interest in
the function of liver in IgA-associated nephritis. Gormly et al
[29] rendered rats cirrhotic by carbon tetrachloride treatment.
Immunohistological examination of the renal tissues from these
rats revealed intense IgA, C3, and to a lesser extent IgG and
1gM deposits in the mesangium and peripheral capillary loops.
Increased levels of serum IgA, C3, and circulating immune
complexes, quantitated by Clq assay, were also noted in these
animals.
Melvin et al [30] also investigated the effect of hepatobiliary
dysfunction on the glomerulus. Selective and progressive in-
crease in mesangial deposits of IgA, C3, and SC was observed
in bile duct ligated rats. Light and electron microscopy exami-
nation, however, revealed no significant difference between the
bile duct ligated and sham—operated rats. Increase in serum
levels of IgA and C3 were also detected in the experimental
group.
Similar observations were made by Emancipator et al [31]. In
these studies, the effect of bile duct ligation on IgA glomerular
deposition was examined in mice that were orally immunized
with protein antigens or received preformed IgA-IC. This model
confirmed that cholestasis promoted mesangial deposition of
secretory IgA and also enhanced the deposition of IgA-IC when
administered at suboptimal concentrations.
The similarity of findings in these models emphasize the
relationship between liver dysfunction and the development of
mesangial secretory IgA deposits. Caution, however, should be
exercised in extrapolating such information, derived from ma-
nipulated pathophysiologic processes in rodents, to human
diseases. Delacroix et al [32] documented that in patients with
liver disease, biliary obstruction does not result in a significant
increase of serum pIgA. Thus, in humans the SC-dependent
biliary transport plays a much less significant role in removal of
pIgA from plasma than in rats [33]. Kalsi, Delacroix and
Hodgson [34] showed that in patients with alcoholic liver
cirrhosis, a significant portion of the elevated levels of serum
IgA is due to monomeric form of IgA. Thus, there is no
selective disturbance of pIgA metabolism in these patients.
Absence of any detectable SC in association with IgA mesangial
deposits in human disorders would also rule out a SC-depen-
dent pathophysiologic mechanism [35].
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Spontaneous deposition
In a study aimed originally at inducing experimental IgA
nephropathy by oral immunization, Imai et al [361 observed that
nontreated, aging ddY mice developed progressively increased
amounts of mesangial IgA deposits. Spontaneous glomerular
deposits of 1gM, IgG, IgA and C3 were observed early at six
weeks of age. Prominence of glomerular IgA deposits became
noticeable at 40 weeks of age. Concomitant slight decrease in
immunofluorescent intensity of IgG, 1gM, and C3 occurred at
that time. Morphological changes were detectable at 16 weeks.
These consisted of diffuse mesangial proliferation that evolved
with time over 59 weeks to increased mesangial matrix. No
hematuria was detectable in these animals.
Relevance of this model to human disease is difficult to
evaluate, for the glomerulonephritis that develops spontane-
ously in aging mice of several different strains appears related
to immune complexes induced by ubiquitous murine—oncorna-
virus antigens [37, 38]. This would suggest that the murine
models are unsuitable for long—term investigation of IgA-asso-
ciated nephritis (Imai H, personal communication).
Immunopathological considerations
It is evident from the above described models that the
complex clinico-pathologic features of IgA-associated nephritis
cannot be duplicated in a single experimental model. However,
a link between the various experimental models and the clinical
studies can be extrapolated from comparative analysis of the
factors that govern or contribute to renal injury.
The IgA
A unique physical feature of the IgA is its occurrence in
serum in a multimeric form, a mixture of monomers (mIgA) and
polymers (pIgA). The importance of this feature in glomerular
deposition of IgA was first examined in the animal model of
IgA-IC mediated nephropathy [8]. The multimeric IgA, derived
from MOPC-315 myeloma, consisted of 70 to 80% pigA and 20
to 30% migA. To determine which of these two forms was
nephritogenic, IgA-IC prepared in vitro or induced in vivo with
either purified mIgA or pIgA and DNP-BSA were examined.
Only pIgA-IC were observed to deposit in the kidneys.
Several clinical studies addressed similar questions [39—42].
These studies postulated that the predominance of subclass
IgAl or IgA2 in the renal deposits of patients with IgA-
associated nephritis would represent mIgA or pIgA, respec-
tively. The relationship between multimeric IgA composition
and subclass distribution in normal human serum has been
defined by the use of IgA subclass specific monoclonal antibod-
ies and IgA size analysis [43]. It was shown that mIgA consti-
tutes 87% of total serum IgA, with 68% IgAl and 19% IgA2;
pIgA represents the remaining 13% of total serum IgA, with
10% IgAl and 3% IgA2. A recent report by Crago et al [44]
showing the concomitant distribution of IgAl and IgA2 produc-
ing cells in the mucosal and other human tissues also spurns the
suggestion that predominance of IgA2 in the glomerular depos-
its would be indicative of mucosal source [39]. Thus, immuno-
histochemical detection of IgAl or IgA2 in renal tissues does
not necessarily correlate with the origin or molecular form of
IgA.
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Fig. 1. Glomerular deposition of immune complexes prepared with
monomeric (migA) and polymeric IgA (pIgA). The pIgA is represented
in a dimer form. Covalently cross—linked mIgA complexes (mLgA-X-
linked) were prepared by mixing mIgA anti-DNP with affinity labeling
antigen, DNP-ester of glutaryl-aminoethyl-carboxymethyl Ficoll.
(Based on data from Ref. 49).
Elevation in levels of serum pIgA has been observed in
patients with primary IgA nephropathy or Schonlein—Henoch
purpura [45]. Predominance of pIgA in mesangial deposits of
patients with primary IgA nephropathy was identified by im-
munofluorescent staining for J-chain and immunochemical anal-
ysis of renal eluates separated by density gradient ultracentri-
fugation [46]. Several other studies, using a variety of analytical
techniques, have confirmed the predominance of pIgA in
mesangial deposits of IgA-associated nephritis [9, 46—48].
Concurrence of the experimental and clinical observations on
the importance of pIgA in IgA-associated nephritis led to
further investigations aimed at elucidating the characteristics
responsible for glomerular deposition of pigA-IC [49]. As
illustrated in Figure 1, size analysis, by gradient polyacrylamide
gel electrophoresis, of mIgA anti-DNP and DNP-Ficoll immune
complexes revealed the formation of only small—size complexes
that failed to deposit in the kidneys. Failure of mIgA to form a
large—lattice is due to its monovalent reactivity toward a large
antigen [50]. In contrast, pIgA anti-DNP and DNP-Ficoll anti-
gen formed large— and intermediate—size complexes that re-
sulted in glomerular deposition. The critical role of complex
size was verified by demonstrating that large mIgA-IC, pre-
pared by covalent cross—linking of mIgA anti-DNP with a
multivalent DNP-affinity—labeling antigen, deposited in the
mesangium in a pattern indistinguishable from that of pIgA-IC.
The affinity of pIgA-IC, as an IgA aggregate, for the glomer-
ular mesangium is consistent with findings in other experimen-
tal systems that demonstrated mesangial deposition of a variety
of macromolecular aggregates [51]. Although preformed mIgA-
IC lack such mesangial affinity, because of size restrictions, this
does not rule out in situ formation of migA-IC [52]. Such
complex formation could result from the interaction of circu-
lating mIgA with specific antigenic determinants available on
pIgA-IC deposited in the mesangium.
All these observations and findings pose an important ques-
tion. Does IgA alone mediate renal tissue injury? Although a
definitive answer is not yet available, negative clues have
4 Rifai
emerged from two experimental models. First, in the mouse
model of chronic oral immunization [24], mesangial IgA and
specific antigen deposits failed to induce any renal function or
significant histopathological changes. Second, in the hepatobil-
iary dysfunction model of bile duct ligated rats, mesangial
deposits of IgA and C3 did not induce either renal or morpho-
logical changes [30]. Factors responsible for the progression of
the disease after mesangial IgA deposition awaits further clar-
ification.
The antigen
One of the most poorly defined areas in IgA-associated
nephritis is precise identification of the antigen involved. The
close temporal relationship between a respiratory or gastroin-
testinal infection and episodes of hematuria has been reported
as a frequent clinical feature [1—31.
The possible role of viral antigens has been suggested re-
cently in studies that demonstrated IgA antibodies eluted from
renal tissues of patients with primary IgA nephropathy bound to
nuclear regions of tissue—cultured cells infected with the same
patient's tonsillar extracts [53]. The antigenic reactivities of the
eluted antibodies, however, were heterogenous because only
10% of the cases had IgA that reacted with cells infected with
tonsillar cell extracts obtained from other IgA nephropathy
patients. Equivalent, but not similar, experimental observations
were made in the Aleutian mink disease [54]. Elution of
diseased kidneys yielded antibodies that bound to particulate
antigen in cells of diseased mink. Despite the reproducibility of
the Aleutian mink disease, intensive research efforts have failed
thus far to identify the nature of the antigen in diseased kidneys.
Insurmountable difficulties in this regard may be encountered at
the clinical level due to the unknown etiology and unpredict-
ability of IgA-associated nephritis.
Any enthusiasm for future development of an experimental
model to simulate nephritis of viral etiology should be tempered
by potentially equivalent role for bacterial antigens. The asso-
ciation of IgA nephropathy with several different bacterial
infections has been reported [1, 55]. Experimentally, Isaacs and
Miller [23] used B512 dextran, extracted from Leuconostoc
mesenteroides, as an example of bacterial antigen to induce
nephritis in mice. The native neutral dextran elicited only mild
mesangial reactivity. In contrast, dextrans highly charged by
chemical modification resulted in pronounced renal histopath-
ological changes.
Induction of circulating IgA-IC by dietary antigens has been
observed in primary IgA nephropathy patients [56]. The impor-
tance of such antigens in the evolution of renal lesions in
IgA-associated nephritis remains speculative. There is no his-
tochemical evidence that such antigens are deposited in the
affected kidneys. In the mouse model of chronic oral immuni-
zation, all the stimulating antigens presented in a dietary form
are detectable along with the specific IgA in the mesangial
deposits [24].
These observations suggest the antigen repertoire in IgA-
associated nephritis is diverse. This diversity may be reflected
by the spectrum of renal histopathologic changes and the
differences in clinical manifestations. Whether the initial or a
different antigen is associated with each recurrent episode
remains to be established. The likely variability in antigenic
composition of IgA-IC during the chronic course of IgA-
associated nephritis in humans complicates any effort to de-
velop a single experimental model for defining the role of
antigen in this syndrome.
Complement
The role of complement in IgA-associated nephritis is un-
known. Immunofluorescent studies typically show C3 mesan-
gial deposits, in a pattern similar to IgA distribution. In con-
trast, Clq and C4 usually are absent from the deposits. Serum
levels of C3 and other complement components are usually
normal during the nephritis [57]. Recently, Tomino et al [58]
suggested that sera of patients with primary IgA nephropathy
are impaired in their ability to mediate solubilization of glomer-
ular IgA-IC deposits. The ability of human IgA to activate
complement, however, remains controversial. An unconfirmed
preliminary report suggested human aggregated IgA activates
C3 [59]. Activation due to the use of bis-diazonium benzidene
for aggregating IgA in this study was not ruled out.
The effect of C3 on renal localization of IgA-IC was evaluated
experimentally in two groups of mice that received IgA anti-
DNP and DNP-BSA complexes [81. In one group, C3 was
depleted by the administration of cobra venom factor. Animals
in the other group served as controls with normal complement
levels. The results indicated that neither complement depletion
in the first group, nor C3 glomerular deposition in the control
group, correlated IgA-IC glomerular deposition or the histo-
pathologic changes. Activation of C3 by the IgA-DNP-BSA
complexes may have been induced by the antigen aggregation.
Konig et al [60] demonstrated that DNP-conjugated antigens
activate C3 in vitro via the alternative pathway. This activation
depends on the degree of DNP-substitution, with highly substi-
tuted antigens being very efficient activators. Insoluble mouse
IgA-IC, prepared with eiher DNP- or diazophenyiphosphoryl
choline—substituted antigens, have been shown to cleave but
not fix C3 in vitro [61, 62]. Again, the possibility of the antigen
rather than the IgA in complex activating C3 has not been ruled
out.
It has been assumed that renal injury in IgA-associated
nephritis is mediated by C3 co-deposited with the IgA in the
mesangium. The experimental findngs that C3 and IgA mesan-
gial deposits in bile duct ligated rats, without concomitant
histopathological changes, challenge this assumption. Clinical
observations of C3 and IgA mesangial deposits in morphologi-
cally normal kidneys are in agreement with the experimental
findings.
Defective clearance
The role of defective IgA clearance in the pathogenesis of
IgA-associated nephritis remains poorly understood. This is
due in part to the lack of information regarding the normal
mechanisms that are called upon to handle and dispose of
IgA-IC.
Experimentally, removal of IgA-IC from circulation of mice
is dependent on lattice—size [63]. In these studies, a complex
size equivalent to 4 dimer IgA or 8 migA molecules was defined
as a minimal size for rapid elimination. The liver is the major
organ responsible for removal of IgA-IC. Recently, a specific
receptor that mediates binding and clearance of IgA-IC was
identified on Kupifer cells [64]. It should be pointed out that the
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Table 1. Summary of immunopathological findings in experimental models for IgA-associated nephritisa
Animal model Antigen
Glomerular depositsb .Histopathological
changes
Urine
abnormalities Reference1gM IgG IgA C3
Immune complexes DNP-BSA
Dextran"
—
—
—
—
+
+
+
?
Mild
Mild
Hematuria
ND
8
10
Systemic immunization Dextranc + — + + Mild/Moderate Normal 21
Oral immunization BGG,Fer,OVA — — + — Normal Normal 22
Viral infection LCM
ADV
—
±
+
±
+
+
+
+
Moderate
Severe
ND
Proteinuria
23
24
Hepatobiliary dysfunction Unknown
Unknown
Unknown
+
—
—
+
—
—
+
+
+
+
+
+
Mild
Normal
Normal
Normal
Normal
Normal
27
28
29
Spontaneous Unknown + + + + Moderate Proteinuria 34
a Abbreviations are: ADV, Aleutian disease virus; BGG, bovine gamma globulin; DNP-BSA, dinitrophenylated bovine serum albumin; Fer,
ferritin; LCM, lymphocytic choriomeningitis; ND, not determined; OVA, chicken egg albumin.b Presence (+) or absence (—) of immune deposits, not intensity of immunofluorescent staining
C Defined charge (p1 <3 to >10) and size (1 x i0 to 5 x l0 dalton)
nature of the antigen may also modulate the clearance and
hepatic uptake of immune complexes [65, 66].
Indirect evidence for a similar mechanism of removal of IgA
in humans could be derived from clinical reports [67, 68]. These
studies identified characteristic pattern of IgA deposits in liver
sinusoids of patients with alcoholic liver cirrhosis. This sug-
gests an impairment in the removal of IgA-IC by hepatic
sinusoidal cells may result in their glomerular deposition. In this
respect, the association of IgA mesangial deposition and alco-
holic liver disease is well established [69—71].
Recent clinical studies have examined the relation between
splenic clearance of IgG-coated red blood cells and IgA-asso-
ciated nephritis [72—74]. Although abnormalities of splenic
function were detectable in some patients, the mechanism
through which a primary reticulophagocytic defect may con-
tribute to the pathogenesis of IgA-associated nephritis remains
to be identified. Roccatello et al [74] suggested that circulating
IgA-IC may block the IgG Fc-receptor on splenic phagocytes
and account for the defect. Experimentally, however, there is
no evidence to support a cross—reactive clearance mechanism
of IgA-IC and IgG-IC [64, 75]. The presence of immune
complexes containing both IgA and IgG in the circulation of
these patients may explain the discrepancy between the clinical
and experimental observations.
Conclusion
A number of experimental models have been described in
which various immunopathologic mechanisms or factors re-
sulted in glomerular IgA deposits (Table 1). As in the clinical
syndrome, most of these models share and fulfill the diagnostic
criterion of detecting IgA as the predominant immunoglobulin
in renal tissues. The incidental nature of the reported findings in
some models and the complexity of the clinico-pathologic
features of IgA-associated nephritis, however, may account for
the exclusion of other criteria, such as histopathologic changes
and renal dysfunction, in most of the experimental work. An
integrated view of the experimental findings in these models
suggests glomerular IgA deposits evolve as a corollary of an
immune complex formation process. This process could result
from the interaction of a specific antigen and pIgA, produced in
response to chronic mucosal or systemic stimulation as in a
persistent microbial infection. Delayed clearance of such com-
plexes due to saturation or dysfunction of the mononuclear
phagocytes system would enhance their glomerular deposition.
Hepatobiliary dysfunction may also induce glomerular IgA-IC
deposition as a consequence of the liver reduced ability to
remove antigens and increased pIgA immune response [76].
These models collectively offer a significant primary insight into
the immunopathogenetic events that are involved in IgA-asso-
ciated nephritis. Future clinical investigative information, how-
ever, will provide a sound framework for pursuing the advance-
ment of experimental inquiry. Thus, clinical information about
the characteristics of the immune complexes, nature of the
antigens, the role of complement, and the function of the
mononuclear phagocytes and the immune systems will supply
the postulates for new experimental approaches. The testing of
these hypotheses in laboratory models will then provide an
understanding of the basic mechanisms responsible for IgA-
associated nephritis.
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